ReviewWiley interdisciplinary reviews. Nanomedicine and nanobiotechnology2017
Tumor-targeted nanotherapeutics: overcoming treatment barriers for glioblastoma.
Review in Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 79 citations in OpenAlex.
- Mild-Temperature Catalyzed Hydrosilylation for Simplified Carbohydrate Functionalization of Porous Silicon Nanoparticles.Chemistry (Weinheim an der Bergstrasse, Germany) · 2025Article
- Advances in PLGA-Based Drug Delivery Systems for Glioblastoma Treatment.International journal of nanomedicine · 2025Review
- Chemotherapeutic nanoparticles for glioblastoma.Frontiers in oncology · 2025Review
- Artificial intelligence in drug development: reshaping the therapeutic landscape.Therapeutic advances in drug safety · 2025Review
- Development and Biological Characterization of Cancer Biomimetic Membrane Nanovesicles for Enhancing Therapy Efficacy in Human Glioblastoma Cells.Nanomaterials (Basel, Switzerland) · 2024Article
- Biocompatible and bioactivable terpolymer-lipid-MnOMaterials today. Bio · 2024Article
- Glioblastoma Therapy: Past, Present and Future.International journal of molecular sciences · 2024Review
- Nanotechnology as a new strategy for the diagnosis and treatment of gliomas.Journal of Cancer · 2024Review
- Nanoparticle-Based Combinational Strategies for Overcoming the Blood-Brain Barrier and Blood-Tumor Barrier.International journal of nanomedicine · 2024Review
- Platinum-Based Nanoformulations for Glioblastoma Treatment: The Resurgence of Platinum Drugs?Nanomaterials (Basel, Switzerland) · 2023Review
- Transferrin-modified chitosan nanoparticles for targeted nose-to-brain delivery of proteins.Drug delivery and translational research · 2023Article
- Customizing delivery nano-vehicles for precise brain tumor therapy.Journal of nanobiotechnology · 2023Review
- Recent Advances on Surface-Modified GBM Targeted Nanoparticles: Targeting Strategies and Surface Characterization.International journal of molecular sciences · 2023Review
- Optimization of Tumor Targeting Gold Nanoparticles for Glioblastoma Applications.Nanomaterials (Basel, Switzerland) · 2022Article
- Advances in Preclinical/Clinical Glioblastoma Treatment: Can Nanoparticles Be of Help?Cancers · 2022Review
- Effect of axitinib regulating the pathological blood-brain barrier functional recovery for glioblastoma therapeutics.CNS neuroscience & therapeutics · 2022Article
- Article
- SapC-DOPS as a Novel Therapeutic and Diagnostic Agent for Glioblastoma Therapy and Detection: Alternative to Old Drugs and Agents.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Nanoformulation Shows Cytotoxicity against Glioblastoma Cell Lines and Antiangiogenic Activity in Chicken Chorioallantoic Membrane.Pharmaceutics · 2021Article
- Rethinking CRITID Procedure of Brain Targeting Drug Delivery: Circulation, Blood Brain Barrier Recognition, Intracellular Transport, Diseased Cell Targeting, Internalization, and Drug Release.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
Glioblastoma (GBM) is a highly aggressive and lethal form of primary brain cancer. Numerous barriers exist to the effective treatment of GBM including the tightly controlled interface between the bloodstream and central nervous system termed the 'neurovascular unit,' a narrow and tortuous tumor extracellular space containing a dense meshwork of proteins and glycosaminoglycans, and genomic heterogeneity and instability. A major goal of GBM therapy is achieving sustained drug delivery to glioma cells while minimizing toxicity to adjacent neurons and glia. Targeted nanotherapeutics have emerged as promising drug delivery systems with the potential to improve pharmacokinetic profiles and therapeutic efficacy. Some of the key cell surface molecules that have been identified as GBM targets include the transferrin receptor, low-density lipoprotein receptor-related protein, α
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.